Chimeric Therapeutics remains suspended from ASX trading after failing to lodge its FY2026 financial statements, with the company reporting an approximate $7.7 million net asset deficiency and unresolved creditor negotiations. Potential recapitalisation interest has emerged, but no binding funding or settlement agreement has been reached.
- ASX suspension continues after FY2026 accounts miss the 30 September deadline
- Approximate $7.7 million net asset deficiency and material going concern uncertainty
- Creditor settlements, including with the convertible note holder, remain unresolved
- Recapitalisation interest is conditional and no binding proposal has been received
- Board reduced as Phillip Hains becomes Interim Chair and Rebecca McQualter Managing Director
Trading Suspension Extends as Accounts Remain Outstanding
Chimeric Therapeutics Limited (ASX:CHM) has missed the 30 September deadline for lodging its FY2026 financial statements, leaving its securities suspended under ASX Listing Rule 17.5. The company said the audited accounts have been delayed while it negotiates unconditional agreements with creditors and works on a possible recapitalisation.
The suspension is expected to remain in place until the financial statements are lodged and ASX is satisfied that Chimeric has met the requirements for reinstatement. That leaves shareholders without a market for the securities while the company attempts to resolve both its balance-sheet position and the outstanding reporting obligation.
$7.7 Million Net Asset Deficiency Drives Creditor Talks
Chimeric said its Preliminary Final Report, lodged on 31 August, recorded a net asset deficiency of approximately $7.7 million. The FY2026 statements are expected to include a material uncertainty related to going concern, while the company has reduced its activities to care and maintenance.
Negotiations are continuing with creditors, including the holder of Chimeric's convertible notes. The stated aim is to settle valid and agreed liabilities at a level that can be met from the company's current financial resources, through binding deeds of settlement. No agreement has been reached, and Chimeric gave no certainty on the timing or outcome.
Recapitalisation Interest Remains Conditional
Several parties have expressed interest in providing capital, including support for a deeply discounted rights issue that would give existing shareholders an opportunity to participate. But each expression of interest is conditional, including on a satisfactory creditor outcome, and the company has received no binding proposal.
That sequencing is important: Chimeric has said creditor settlements are a condition of any recapitalisation, while a successful funding process may be needed to support the company's next phase. Until both pieces are resolved, the proposed rights issue and other funding possibilities remain preliminary rather than executable transactions.
Board Downsized as US Operations Wind Back
The company has significantly reduced its US operations, including closing out its Phase I clinical study and reducing US-based employees. Its CORE NK investigator-led study remains ongoing, but Chimeric said it requires no funding or support from the company.
Against that reduced operating footprint, Brad Glover and Lesley Russell have retired as directors. Chief Executive Dr Rebecca McQualter has joined the board as Managing Director, with no change to her employment terms or remuneration, while Phillip Hains has become Interim Chair. The board now comprises Hains, Miles Prince and McQualter.
The immediate investment question is not simply whether Chimeric can attract new capital, but whether it can first convert expressions of interest into binding creditor settlements and a workable recapitalisation. Until that happens, the overdue audited accounts and ASX reinstatement requirements remain the decisive gates.
Bottom Line?
Chimeric's path back to trading depends first on binding creditor settlements, then on a recapitalisation with terms that have not yet been defined.
Questions in the middle?
- Can Chimeric reach unconditional settlements with its creditors using its current financial resources?
- Will any recapitalisation proposal become binding, and how heavily could existing shareholders be diluted?
- When will the audited FY2026 financial statements be lodged and ASX reinstatement requirements satisfied?